Literature DB >> 22842333

Effects of conditioning regimens and T cell depletion in hematopoietic cell transplantation for primary immune deficiency.

Brandon M Triplett1, Chong Wang, Jie Yang, Mari Dallas, Christine Hartford, Vanessa Howard, Asha Pillai, David Shook, Ashok Srinivasan, Joseph Laver, Wing Leung.   

Abstract

This study analyzes the hematopoietic cell transplantation experience in patients with immune deficiency at a single institution. The objective is to comprehensively evaluate the short-term and long-term outcomes with various preparative regimens, donor grafts, and ex vivo manipulations to identify transplantation approaches that most likely favor early donor immune competency without generating excessive toxicity. Clinical outcomes were evaluated in 52 consecutive patients with immune deficiencies. Thirty-seven of the 52 patients (71%) survived with attenuation of their underlying disease. The use of a melphalan-based reduced-intensity conditioning preparative regimen and immunomagnetic CD3(+) T cell depletion techniques (when T cell depletion was indicated) were associated with improved event-free survival. Survivors who received a preparative regimen other than a melphalan-based reduced-intensity regimen suffered from therapy-related morbidities or chronic/recurrent infections. Our findings indicate that melphalan-based reduced-intensity conditioning regimens and immunomagnetic CD3(+) T cell depletion limit therapy-related toxicity, and demonstrate promising results for the early establishment of donor immune competency.
Copyright © 2012 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22842333      PMCID: PMC3496815          DOI: 10.1016/j.bbmt.2012.07.014

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  29 in total

1.  Secondary solid cancers after allogeneic hematopoietic cell transplantation using busulfan-cyclophosphamide conditioning.

Authors:  Navneet S Majhail; Ruta Brazauskas; J Douglas Rizzo; Ronald M Sobecks; Zhiwei Wang; Mary M Horowitz; Brian Bolwell; John R Wingard; Gerard Socie
Journal:  Blood       Date:  2010-10-06       Impact factor: 22.113

2.  Stem cell transplants for patients with X-linked agammaglobulinemia.

Authors:  Vanessa Howard; Laurie A Myers; David A Williams; Gary Wheeler; E Victoria Turner; John M Cunningham; Mary Ellen Conley
Journal:  Clin Immunol       Date:  2003-05       Impact factor: 3.969

3.  Impact of donor type on outcome of bone marrow transplantation for Wiskott-Aldrich syndrome: collaborative study of the International Bone Marrow Transplant Registry and the National Marrow Donor Program.

Authors:  A H Filipovich; J V Stone; S C Tomany; M Ireland; C Kollman; C J Pelz; J T Casper; M J Cowan; J R Edwards; A Fasth; R P Gale; A Junker; N R Kamani; B J Loechelt; D W Pietryga; O Ringdén; M Vowels; J Hegland; A V Williams; J P Klein; K A Sobocinski; P A Rowlings; M M Horowitz
Journal:  Blood       Date:  2001-03-15       Impact factor: 22.113

4.  Bone-marrow transplantation in a patient with the Wiskott-Aldrich syndrome.

Authors:  F H Bach; R J Albertini; P Joo; J L Anderson; M M Bortin
Journal:  Lancet       Date:  1968-12-28       Impact factor: 79.321

5.  Evaluation of survival data and two new rank order statistics arising in its consideration.

Authors:  N Mantel
Journal:  Cancer Chemother Rep       Date:  1966-03

6.  Nonmyeloablative stem cell transplantation for congenital immunodeficiencies.

Authors:  P Amrolia; H B Gaspar; A Hassan; D Webb; A Jones; N Sturt; G Mieli-Vergani; A Pagliuca; G Mufti; N Hadzic; G Davies; P Veys
Journal:  Blood       Date:  2000-08-15       Impact factor: 22.113

7.  Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy.

Authors:  Salima Hacein-Bey-Abina; Françoise Le Deist; Frédérique Carlier; Cécile Bouneaud; Christophe Hue; Jean-Pierre De Villartay; Adrian J Thrasher; Nicolas Wulffraat; Ricardo Sorensen; Sophie Dupuis-Girod; Alain Fischer; E Graham Davies; Wietse Kuis; Lilly Leiva; Marina Cavazzana-Calvo
Journal:  N Engl J Med       Date:  2002-04-18       Impact factor: 91.245

8.  Long-term survival and transplantation of haemopoietic stem cells for immunodeficiencies: report of the European experience 1968-99.

Authors:  Corinne Antoine; Susanna Müller; Andrew Cant; Marina Cavazzana-Calvo; Paul Veys; Jaak Vossen; Anders Fasth; Carsten Heilmann; Nicolas Wulffraat; Reinhard Seger; Stéphane Blanche; Wilhelm Friedrich; Mario Abinun; Graham Davies; Robert Bredius; Ansgar Schulz; Paul Landais; Alain Fischer
Journal:  Lancet       Date:  2003-02-15       Impact factor: 79.321

9.  Umbilical cord blood transplantation in Wiskott Aldrich syndrome.

Authors:  Alan P Knutsen; Marsha Steffen; Kris Wassmer; Donna A Wall
Journal:  J Pediatr       Date:  2003-05       Impact factor: 4.406

Review 10.  Molecular defects in human severe combined immunodeficiency and approaches to immune reconstitution.

Authors:  Rebecca H Buckley
Journal:  Annu Rev Immunol       Date:  2004       Impact factor: 28.527

View more
  4 in total

1.  Successful haploidentical donor hematopoietic stem cell transplant and restoration of STAT3 function in an adolescent with autosomal dominant hyper-IgE syndrome.

Authors:  N C Patel; J L Gallagher; T R Torgerson; A L Gilman
Journal:  J Clin Immunol       Date:  2015-05-12       Impact factor: 8.317

2.  Long-term outcomes of fludarabine, melphalan and antithymocyte globulin as reduced-intensity conditioning regimen for allogeneic hematopoietic stem cell transplantation in children with primary immunodeficiency disorders: a prospective single center study.

Authors:  A A Hamidieh; M Behfar; Z Pourpak; S Faghihi-Kashani; M R Fazlollahi; A S Hosseini; M Movahedi; M Mozafari; M Moin; A Ghavamzadeh
Journal:  Bone Marrow Transplant       Date:  2015-11-23       Impact factor: 5.483

Review 3.  Haploidentical bone marrow and stem cell transplantation: experience with post-transplantation cyclophosphamide.

Authors:  Tara M Robinson; Paul V O'Donnell; Ephraim J Fuchs; Leo Luznik
Journal:  Semin Hematol       Date:  2016-01-15       Impact factor: 3.851

Review 4.  Considerations in Preparative Regimen Selection to Minimize Rejection in Pediatric Hematopoietic Transplantation in Non-Malignant Diseases.

Authors:  Robert J Hayashi
Journal:  Front Immunol       Date:  2020-10-19       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.